Good morning, ladies and gentlemen. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Verano Holdings Corporation Fourth Quarter and Full Year 2023 Earnings Conference Call. Today's conference is being recorded, and all lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during that time, simply press the star key followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one a second time. Thank you, and I will now turn the conference over to Julianna Patera, Vice President of Investor Relations. You may begin. Thank you, and good morning, everyone. Welcome to Verano's Fourth Quarter and Full Year 2023 Earnings Conference Call. I am joined today by George Archos, Chief Executive Officer and Founder; Brett Summerer, Chief Financial Officer; Darren Weiss, President; and Aaron Miles, Chief Investment Officer. During this call, we will discuss our business outlook and make forward-looking statements within the meaning of applicable U.S. and Canadian securities laws, which are based on management's current assumptions and expectations. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, and achievements of the business or developments in the company's industry to differ materially from those implied by such forward-looking statements. Actual events or results could differ considerably due to risks and uncertainties mentioned in our filings on EDGAR and CR, including our financial statements for the year and quarter ended December 31, 2023. All financial results for the fourth quarter and year ended December 31, 2023, and related comparisons to prior periods included in this release have not been audited and were prepared by the company prior to the release of the company's independent auditor's audit report. In addition, throughout today's discussion, we will refer to non-GAAP financial measures that do not have any standardized meaning prescribed by GAAP. Management believes that non-GAAP results are useful to enhance the understanding of the company's ongoing performance, but these are supplemental to and should not be consideration in isolation from or as a substitute for GAAP financial measures. These non-GAAP measures are defined in our earnings press release and available on our website at investors.verano.com, which also includes the reconciliation of these measures to their respective, most directly comparable GAAP financial measures. Lastly, all currency is in U.S. dollars unless otherwise noted. George, please take it away. Thank you for joining today, and I hope everyone had a nice start to the year. I am very proud to discuss this past year's results with you, along with the many milestone achievements led by our hardworking team here at Verano. Today, I will provide an overview of the fourth quarter and full year 2023, followed by a deep dive into some of our larger markets before passing it off to Brett to cover the financials in more detail. I will then close with my thoughts on our outlook for 2024 and the many opportunities that lie ahead of both the industry and Verano specifically. To start, we delivered against our full year 2023 Free Cash Flow guidance, generating $73 million in Free Cash Flow, what we expect may be the largest for the industry in 2023, given peer guidance. We had a record year with $938 million in revenue or 7% growth versus the prior year, and we maintained our focus on price and cost management, which helped us drive 32% Adjusted EBITDA margins for the year, supported by a strong vertical mix and a disciplined pricing strategy. We continued to execute against our growth strategy, targeting practical pockets of growth across our retail footprint and product portfolio. Throughout 2023, we added 16 dispensaries across key markets, including Florida, Connecticut, Pennsylvania, and West Virginia, bringing our year-end dispensary count to 136. We have also continued building out throughout 2024 and now stand at 138. Along with retail growth, our innovation pipeline was humming all year, evidenced by our over 70 new products deployed across our multi-state footprint. For example, Savvy and Bits, two of our younger brands, grew to represent a combined 22% of our total net revenue within just a year of their launch, and the entire Verano product portfolio gained over 225 basis points in market share throughout the year across our BDSA trackable markets. We focused on leveraging the strong brand portfolio to take advantage of organic growth opportunities, including new adult use markets. Notably, we continued to be an early leader in markets that transitioned to adult use. I n Connecticut and Maryland, both of which transitioned to adult use in 2023, we were able to smoothly execute two successful program launches, as defined by improved output metrics in both markets. By strategically timing our hiring to align with our projected growth and maintaining an eye for efficiencies, these two markets saw average units produced by headcount increase 47% during the first quarter of adult use sales as compared to their prior quarters. In that same vein of efficiencies, automation continues to be a priority for us as we delivered continued cost savings and enhanced operating procedures. We implemented additional automation measures across New Jersey, Illinois, and Florida, which contributed to an improvement of 26% for units produced per headcount across those three states for 2023, off an already strong base in 2022. We believe automation is critically important to the business and plan to continue investments in efficiencies as we see the opportunity to do so. We continue to partner with industry representatives in state lobbying efforts, which bore many victories, with Illinois, New Jersey, and Connecticut all decoupling cannabis from the 280E tax burden. We commend these three states for implementing a fair tax scheme that will better equip small cannabis businesses to succeed and thrive. These three states represent some of our top wholesale and retail contributors, and their fair approach helped us save $16 million in tax liabilities in 2023.... Though I hesitate to use the word savings, as that implies we are somehow now tax-advantaged versus other industries in the state, when in fact, we are only now taxed alongside them against our taxable income. Imagine the formidable cash flow potential we'd have if and when 280E is decoupled from all of our states and at the federal level. Regarding capital allocation, we believe we delivered on our goals made one year ago to leverage our real estate and improve mortgage rates, efficiently manage through our balance sheet and tax payments, and build cash for flexibility. We completed over $50 million in real estate loans in 2023, including both lower cost of capital new loans, as well as refinancings, maintaining a reduced blended cost of capital versus lease-heavy peers. Additionally, as we previously guided, we maintained our income tax payable balance, ending the year at similar levels compared to the prior year. Finally, after growing our cash balance through the year by $90 million to a year-end balance of $175 million, we plan to put this cash to use and reduce our leverage on higher cost of capital debt. Flexibility in the credit agreement allows for nimbleness, should any anticipated opportunities arise, given the current political landscape. We have scheduled a prepayment under our senior credit facility of $50 million for April thirtieth, leaving us optionality to further pay down the credit facility at a time of our choosing, subject to advance notice obligations and potential prepayment premiums. For context, this $50 million in debt reduction will result in about $8 million in interest expense saving annually. Moving on to updates from some of our larger markets, I'd like to begin with New Jersey. As we noted last quarter, given the continued ramp-up and normalization of dispensary count in the state, retail revenue declined to $26 million in the fourth quarter. Again, this was in line with our expectations. Keep in mind that at the beginning of 2023, there were only 19 dispensaries in the state, and by the end of the year, there were over 90. While we expect this market to remain competitive as additional dispensaries open, we have the opportunity to open 7 social equity JVs, which we believe will help to offset increased competition. In the near term, however, we expect first quarter retail sales in the state to decline sequentially. On the wholesale side, the fourth quarter showed continued strength with our brand portfolio amongst the market share leaders for the state, according to BDSA. Additionally, we feel that state dispensary openings will continue to offer wholesale opportunity this year, especially given Verano's strong brand awareness and popularity in New Jersey with cannabis consumers. Illinois shares some similarities with New Jersey in that many social equity dispensaries have opened and represent an increasingly competitive retail environment. However, we've developed an arsenal of new brands to combat this and grow our market share, such as the recent relaunch of the Essence brand on Green Wednesday, which contributed to significant market share gains. Throughout the fourth quarter, we increased our market share by over 20%, elevating us to the number 3 position in the state, according to BDSA. Illinois remains a key state for us, given the state's strong wholesale pricing versus the national average, and its over $2 billion of sales in 2023, which put it in the top 5 U.S. cannabis markets. In Florida, we exceeded our expectations for the quarter, with revenue up nearly 11% sequentially. While we opened three new dispensaries there during the quarter, much of this outperformance was driven by market share gains. MÜV had an impressive quarter, gaining 90 basis points of market share as measured by ounces sold versus the prior quarter. It bears worth repeating that we believe our market share as measured by volume, understates our true market share of sales, given our premium pricing position. We believe this recent market share increase was due to our deeper product offering and focus on quality versus peers. Notably, we also achieved these gains while maintaining our premium pricing position relative to peers and with lower levels of discounting versus the prior year period. With support still trending quite favorably, we believe that Florida voters will approve the legalization of adult use consumption. In preparation, we anticipate opening a handful of new dispensaries this year and are already incrementally adding capacity in our Florida production facilities to meet both current medical and future demand. We look forward to what we believe will be a very sunny future in Florida. In Pennsylvania, adult use momentum has continued, which we believe may ultimately result in a 2025 adult use launch, given the strong support from the governor. With our 18 dispensaries, over 60,000 sq ft of cultivation, and our expectation for a 2x-3 x lift in revenue upon adult use commencement, we will be watching the Commonwealth very closely. Lastly, we are preparing for the much-anticipated launch of adult use in Ohio. We are ramping up capacity and plan on adding 1 dispensary to today's 5 dispensary footprint, bringing our total to 6. Given the significance of a new adult use program launch, we are optimizing everything in the state from SOPs to retail operations. Our expected 2.5 x revenue lift, similar to that of Connecticut and Maryland, should provide a modest top-line tailwind in 2024. Before I pass the call to Brett, I want to take a minute to thank our teammates across the country for an outstanding job in 2023. I am so grateful for our team's efforts, proven by the great results we delivered for the year. Not only did we accomplish a great deal, but we have a proven track record of delivering against our promises. Now I'll pass it off to Brett to speak to our financials in more detail. Thanks, George. I'll begin by covering full year results before diving into fourth quarter results.... Revenue for the full year increased 7% year-over-year to $938 million, driven by a full year's contribution from New Jersey adult use, in addition to adult use launches in Connecticut and Maryland. On a gross revenue basis, excluding intersegment eliminations, 68% of sales were derived from the retail business, with the largest contributions from Florida, Illinois, and New Jersey. The remaining 32% of sales were derived from the wholesale side of the business, with the largest contributions from Illinois, New Jersey, and Connecticut. Gross profit for the year was $475 million, or 51% of revenue, versus $423 million or 48% of revenue in the prior year. The gross profit increase was driven by increased vertical mix of Verano products, as well as favorable market mix, paired with an overall top-line growth and continued operational performance improvements. We also reduced inventory by 15 days year- over- year, ending with 108 days of inventory on hand, which we feel is a comfortable level. SG&A expenses were $332 million for the year, or 35% of revenue, versus $357 million in the prior year, or 41%. The decline in SG&A expense was largely driven by a decrease in employee stock compensation relative to the prior year. We had a net loss for the year of $113 million, driven by the provision for income taxes, as we still account for income taxes in our 280E, as well as an impairment associated with our Arizona cultivation reporting unit. Adjusted EBITDA for the year was $305 million or 32% of revenue. Moving on to the financials for the fourth quarter of 2023, revenue was $237 million, up 5% year-over-year, primarily due to growth in New Jersey wholesale, in addition to growth in Maryland and Florida retail. Gross profit for the quarter was $118 million, or 50% of revenue, versus $103 million, or 46% of revenue in the prior year period, driven by increased wholesale revenue paired with lower cultivation supply costs. SG&A expenses were $86 million for the quarter, or 36% of revenue, versus $81 million in the prior year period, or 36% of revenue. Relative to revenue, expenses were kept flat as we balanced store opening costs with business growth. We had a net loss for the fourth quarter of $73 million, again, driven by income taxes and impairment of our Arizona cultivation reporting unit. Adjusted EBITDA was $73 million or 31% of revenue. Excluding some inventory impacts, sequential performance was strong. Turning to the balance sheet and cash flows, we maintained a strong balance sheet, ending the year with $175 million in cash and cash equivalents, which provides us flexibility, whether it be through continued deleveraging, further income tax paydown, CapEx, or M&A. Cash flow from operations for the year was a very strong 110 million, contributing to our free cash flow of $73 million for the year, meeting our guidance range. We achieved our free cash flow alongside tax payments, totaling $167 million in 2023, and continued investments in the company, with CapEx spending in the fourth quarter and full year at $10 million and $36 million, respectively. Looking ahead to 2024, we should expect similar levels of CapEx investment this year, anticipating a $25 million-$50 million range, excluding opportunistic activity should any markets expand, such as adult use in Florida. Given the many uncertainties facing the industry this year, we anticipate placing more emphasis on near-term guidance. Looking towards the first quarter, we're expecting a 5%-7% revenue decline versus the prior year period due to competitive pressures in New Jersey. Additionally, we anticipate a similar inventory-related adjusted EBITDA impact, albeit more subtle in the fourth quarters. In 2024, we will continue to evaluate the best uses of cash, including opportunities to strengthen our balance sheet and to best position ourselves ahead of growth. Now I'll hand it back to George to wrap up. Thanks, Brett. 2024 looks incredibly positive from where I'm standing, with tailwinds for both our industry and Verano, specifically. Here at Verano, we are expanding our robust innovation pipeline, as evidenced by the success of our newer products, which comprise 47% of revenue as of the end of the year. These products address some key gaps in our portfolio. While we recognize that sustaining over a 40% revenue share from new product launches is likely not sustainable, we remain committed to innovation and are working on some exciting developments that you'll be hearing about as we progress throughout the year. At the retail experience level, we are evaluating initiatives to better monetize our sales force. Additionally, given the ROI we've seen from X or Twitter advertisements, which is now our third largest web traffic acquisition medium, we anticipate slightly increasing our investment in direct marketing expenses this year. We expect to share more developments with you over the next few months. Our legislative affairs team continues to focus on achievable state-level initiatives with high ROI. This year, our team is focused on lobbying for lower various state-level fees, lower consumer-level taxes, psychoactive hemp regulation, 280E decoupling at the state level, and additional legalization campaigns. I am confident our team will make important contributions to create another strong year of incremental, tangible wins for the company. And lastly, we retain our appetite for accretive M&A deals but will remain patient. As we continue evaluating M&A, we will remain focused on identifying opportunities that are not only the right strategic fit, but also financially attractive. Industry-wide, we are, of course, looking ahead to a final rescheduling decision from the DEA. We continue to believe the DEA will agree with the HHS's recommendation to reschedule cannabis from Schedule I to Schedule III. We expect the current administration will want to point to not only a promise, but an achievement. Given the population's strong support of the issue, with 70% of Americans supporting legalization, according to the latest Gallup poll, and the depth of new research underpinning cannabis's medical efficacy. We believe the DEA's possible rescheduling decision should be nothing short of a common sense approach. I'd like to walk through what a Schedule III decision may mean for our business, an important step towards operating as a normal business. Let's start with the tax implications, arguably the most meaningful impact. We anticipate we would finally be taxed as an ordinary business, be able to deduct salary, travel, rent, service provider, and countless other expenses from our taxable income. We estimate not being subject to 280 would have saved us over $80 million in federal and state tax dollars in 2023. Additionally, this would have the potential to significantly improve our credit terms, resulting in lower cost of capital. Our consumers might be able to use credit cards, which we estimate would modestly increase basket sizes. Further, we could have a much less burdensome cash management system, allowing us to earn interest on our significant cash balance. And more importantly, our employees would be safer as we'd anticipate a decrease in break-ins industry-wide, with dispensaries holding less cash on-premises. Our vendor pool could also greatly widen. Lastly, we could expect incremental institutional investor comfort, possibly modestly lifting multiples as new names begin entering the space. Although we don't think a Schedule Three designation alone would be enough for a U.S. listing, we think there's a chance that a Schedule Three decision would continue momentum for certain exchanges. As usual, we remain proactive in that arena. While we cannot predict with certainty if or when any Schedule Three decisions would be made or what effect it will have on our business, we expect that these changes will be positive for Verano. While most are focused on the DEA recommendation, let me remind you of all the other positive catalysts ahead of us, including adult use launches this summer in Ohio and momentum in Pennsylvania and Florida towards adult use legalization, impacts from which cannot be understated. Today, 38 states have a comprehensive medical cannabis program, and conversations continue in the right direction in states without programs, such as South Carolina and North Carolina. With 24 established adult-use state programs, a wealth of opportunity lies ahead of us regarding future adult use program launches. From where we stand, everything is trending in the right direction. I am tremendously proud of the team here at Verano and thank them again for an incredible 2023. As I said at the onset of the call, we have so much to look forward to in 2024. I look forward to seeing what additional momentum this year brings. Operator, please open up the line for questions. And thank you. At this time, I would like to remind everyone in order to ask a question, press Star and then the number 1 on your telephone keypad. If you would like to withdraw your question, press Star 1 a second time. To be able to take as many questions as possible, we ask that you please limit yourself to one question, and we will pause for just a moment to compile the Q&A roster. And we will take our first question from Aaron Grey with Alliance Global Partners. Your line is open. Hi, good morning. Thanks for the question and a nice finish to the year there, and thanks for all the commentary and the prepared remarks. So first question for me, just want at a high level, maybe get some color in terms of how you're seeing pricing pressure. I know it goes a lot market by market, but just any color you could offer in terms of your confidence in maintaining the EBITDA margin above the 30%, despite the guide that you gave, you know, for the first quarter, and then any commentary in terms of the impact you believe New Jersey could have, you know, post the first quarter in terms of continued impact from store saturation within the state. Thank you. Good morning, Aaron. George here. Thanks for the questions. As far as pricing pressure, we're seeing stabilization in quite a few of our markets, but until we see adult use in Ohio, we think there will be additional pricing pressure there. As far as the other markets, again, we're seeing stabilization. New Jersey, I think we're gonna continue to see retail doors open throughout the year. Wholesale business, I think, will continue to decline, but it will be offset by the retail sales decline. Okay, great. Thanks. We will take our next question from Scott Fortune with ROTH Capital Partners. Your line is open. Yeah, good morning. Thanks for the question. Obviously, great job on cash flow, and you mentioned additional cash flow with 280E elimination here, if that comes about, and you continue growing the free cash flow nicely here. But you mentioned priorities or optionality here, looking at to allocate that capital, obviously to pay down debt, taxes. How are you looking at the growth as we look going out to 2024 and potential cash flow, you know, on top of the $25 million-$50 million in CapEx? Just kind of help us understand where growth will come from as you look to allocate your cash priorities from that standpoint. Sure. So thanks for the question. This is Brett. You know, as we look at our growth projection for 2024 and where we're spending our capital, you know, the big one on the table is Florida adult use, and any preparation we need to do there, but obviously any preparation we have for other movements that we might have, given some of the changes recently in the political landscape and the different states that are out there. So I think, you know, any of those opportunities are very high on our list, but we're not saying it's part of our default baseline capital spending. Our baseline capital spending is additional store expansions in Florida, as well as some of the social equity joint venture opportunities that we have in New Jersey and Connecticut. Okay, thank you. We will take our next question from Matthew Bottomley with Canaccord Genuity. Your line is open. Yeah. Good morning, everyone. I'm just wondering if we can get a little more color on the dynamics in New Jersey to end the year. I know it's not perfect information, but some of the, you know, BDSA point of sales data pointed to a pretty healthy Q4, and then, and particularly a pretty, pretty strong December in that market. And if you look at Verano Brands, they seem to be very strong as well, you know, top, top two or competing for top one. So just the declines that we saw sequentially, I'm just wondering if we can triangulate, you know, your experience, specifically in your stores and as an operator relative to what we're seeing in the macro data that a lot of us subscribe to. Hey, good morning, Matt. So let me talk about in Jersey. We're seeing mostly a decline in the retail side of our business. There've been quite a few stores that opened throughout the year. We also had some construction going on at the facility, so we were a little short on flower as we were making some transitions throughout the facility. That'll ramp back up throughout this first quarter and second quarter of 2024. So we're anticipating some good wholesale growth, but like we said earlier, the retail sale decline is real. I mean, we started with 19 stores, and that's grown dramatically throughout the year, and we'll continue to grow this year. So it is what it is. That's a beautiful New Jersey. It's still a great market for us. We're anticipating opening up the additional 7 stores throughout this year and next, as we're looking for locations that will offset some of the retail sales decline. But it's been a strong market, and will continue to be a strong market for Verano's for years to come. Just to add to something that George just said, keep in mind that a dollar of retail is not as valuable as a dollar of wholesale when it comes to New Jersey in that market. So, you know, even though we are seeing, you know, retail sales declines with the competition that comes in the market, we're also selling into additional stores, and that's lifting our margins. We will take our next question from Russell Stanley with Beacon Securities. Your line is open. Good morning, and thank you for the question. Just following up on New Jersey, can you, I guess, elaborate on what kind of penetration you're seeing with those new stores in New Jersey as wholesale customers, how they're behaving, how their buying activity compares to those of MSO customers, for example? Any color there would be helpful. Thanks. Hey, good morning, Russ. Great question. Apparently, you guys love New Jersey today. What we're seeing in the new stores, you know, we're in over 90% of the stores in the state. We're obviously a very strong wholesale provider within New Jersey. But like any new market, new stores start up pretty slowly, so the buying is generally pretty small in the beginning as they continue to ramp up. Sales throughout the state are continuing to climb as there's more access. So generally, we, we anticipate strong wholesale sales as we move forward and the market continues to grow. But like we said earlier, retail on our side is gonna continue to drop until we open some of the new stores. We will take our next question from Andrew Semple with Echelon Capital Markets. Your line is open. Hi there. Thank you for taking my question. Congrats on the results. Just, maybe going into your commentary on margins, you know, the 30% EBITDA margins in the quarter, do you, do you think you can continue to hold the line on, that 30% EBITDA? Items also play out in Q1. So maybe you could speak to that. And then also, how, how much of a benefit are you expecting from, the automation investments that you're making on the overall consolidated, either gross or EBITDA margin profile? That'd be helpful. Thank you. Sure. Thank you for the question. So if you think about our margins this quarter, we were at 31%. Again, 32% for the year. If you adjust out the inventory movement that we had, which we try to talk about, so you've heard me talk multiple times in the past on these calls about the fact that we kind of live in that 59-61% sort of percentage on a gross margin basis, excluding inventory movement. So we did additionally have inventory reduction this quarter as well. We're down it to 108 days. If you were to remove that impact, our gross margins this quarter were actually in the 64-65% range. So from an EBITDA perspective, excluding inventory, we'd be kind of closer to that 36%-37% EBITDA. So actually, even though we, we published the number we did, it was because of inventory reductions that were fairly intentional. So, you know, overall, our margin's very strong, and going into fourth quarter - first quarter, we're seeing, again, some of that, although we're gonna see some repeat, on the inventory reduction as well, but to a lesser degree. Yeah, and I'll speak, this is Darren speaking. I, to automation, obviously, we continue to invest in automation technology. That technology also continues to get better, both in terms of the machinery that's being developed and our own internal team tweaks as we get accustomed to newer technology. So, short term, you know, I don't know that it would be fair to predict what the margin impact would be from a long-term basis. You know, we predict that we're gonna have some serious savings in terms of cost of input. So, very, very excited to, you know, to continue to develop that technology alongside our partners. Great. Very useful. Thank you. We'll take our next question from Sonny Randhawa with Seaport Global Securities. Your line is open. Hi, thanks for taking my question. I just wanted to kind of get a sense of the consumer. I guess last year we saw an acceleration of the value segment, but with inflation slowing, have you seen any changes in terms of consumer trends or preferences in 2024? Good morning, Sonny. I mean, it's too soon to tell. I mean, that's just happening now. Right now, the decline has been still focusing on the value sector, and the brands have done very well there. We just did a relaunch on the Essence, which is more of a mid-tier product. It's gone extremely well for us. So it's gonna take us a little bit more time to assess, and maybe we can answer that on the next call. Great. We will take our next question from Frederico Gomes with ATB Capital Markets. Your line is open. Hi, good morning, and thank you for taking my question. Question is, on Florida. You mentioned you exceeded expectations there. You gained some market share. So just curious, if you could provide a little bit more color on how you were able to achieve that, given your, your premium price and, compared to peers, you know, that also related to a, a bit of, lower pricing pressure there in the market or a change in consumer behavior. Anything that you could add that, to your performance in Florida? Thank you. Hey, good morning. Florida, we had a very strong quarter. Like we said earlier, we've always focused on premium-based products, so the quality of our products are usually higher compared to our peers. That's why we have a higher price point. We feel very comfortable in that space. We've also launched a number of new products throughout the quarter and throughout the year, and we had increased production at our facility, which has also helped our gains. Thank you. We will take our next question from Mike Regan with Excelsior Equities. Your line is open. Hey, good morning. Thanks for the question. Just, I mean, basically, when you were mentioning the potential allocation of, you know, where you could reallocate those, $80 million of potential to DEA savings if we get rescheduling, can you help me sort of understand, your views on how those will be allocated, and in terms of M&A, you know, what would constitute sort of a strategic fit or what you're on the lookout for? Thanks. Yeah. So, you know, cash is fungible, so we see any inflow of additional cash, no different than any other inflow that we would have, whether it's from operations or real estate loans or that sort of thing. So therefore, it hasn't really changed our strategy in terms of where we would redeploy it. Our priorities, as we mentioned before, is to pay off our Chicago Atlantic $100 million one-time prepayment, and then after that, we have obviously a menu of options ahead of us. We're saving or holding back some cash for Florida adult use this year in case that happens. We're also looking at M&A. And in terms of which, how do we prioritize that, we're always looking for the highest ROI for our dollars. So, that always is going to depend upon the business conditions and the environment that we're in at the time. Okay, great. Thanks. We will take our next question from Ty Collin with Eight Capital. Your line is open. Hey, guys. Thanks for the question. Just wanted to ask your thoughts on Ohio with that market potentially flipping to adult use in the fall. And now that we have a little bit of a preview of what the regs might look like, just wanted to get your outlook on that market, the way it's structured, and I'm wondering if there's another market in your portfolio that you might liken it to. Hey, good morning. We're excited about Ohio. I mean, we see it as another 2.5x-3 x lift, similar to Maryland. It's a legacy market for us. We're prepared, and we're excited for the opportunity. We will take our next question from Pablo Zuanich with Zuanich and Associates. Your line is open. Thank you. George, can you clarify a comment you made regarding rescheduling? I mean, you pretty much imply that with rescheduling, you would have everything that's in the Safer Banking bill, right? I think you talked about better credit terms, lower rates, critical usage, better cash management. Are you talking about, I mean, that it would really, Safer Banking would not be necessary if you get rescheduling? Or is it more that just because your cash flow profile improves, you are in a better position in terms of credit? If you can clarify that, thank you. It's just increased momentum. We're assuming all those things come with the rescheduling, but safe banking is just another step, should probably add more positive momentum for cannabis. So if you put the two together, it's just better for our company, better for investors to be able to enter the space. Again, credit cards, banking, all of those things come together, so we'll see how it pans out this year. We're very excited for both of these outcomes, but we think DEA is a higher probability. Right. And then just if I can follow up, you know, Trulieve, this morning, talked about getting about $113 million in tax refunds, as they are fighting the 280E rules. Are you planning to take a similar stance also and, and be maybe, I don't know what's the word, more proactive or more aggressive in asking for refunds, on, on past 280E payments? Thanks. Yeah. Thanks for the question. We're still evaluating exactly what happened with that, just to make sure that, you know, we can support it from our perspective as well. But to the extent that we get comfortable with that, you can be assured that we will very shortly be doing that for ourselves and getting our refunds. Got it. Thank you. We will take a follow-up question from Aaron Grey with Alliance Global Partners. Your line is open. Mr. Grey, did you have any follow-up questions to ask today? Hearing no response, we have no further questions at this time, so I will now turn the call back to Mr. George Archos for closing remarks. Thank you, everyone, for joining the call today, and have a great day. We look forward to seeing you next quarter. Ladies and gentlemen, this concludes today's call, and we thank you for your participation. You may now disconnect.